In non‐small cell lung cancer (NSCLC), epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have been effective in treating EGFR‐mutated lung cancer.1, 2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.